welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Tucson-based drug startup Cancer Prevention Pharmaceuticals Inc. has announced the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to test the company’s flagship drug candidate for preventing gastric cancer.
The drug, CPP-1X, will be studied in patients with precancerous gastric lesions who are at high risk for gastric cancer, the company said Monday.
The trial is funded by the National Cancer Institute and run in collaboration with gastroenterologists Dr. Keith T. Wilson and Dr. Douglas R. Morgan of the Vanderbilt University School of Medicine and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
Genetic Polymorphisms of Human Flavin Monooxygenase 3 in Sulindac-Mediated Primary Chemoprevention of Familial Adeno...PURPOSE : Sulindac is a nonsteroidal ant...
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPAThis purpose of this study is to investi...
Risk-Reducing Surgery in FAP: Role for Surgeons Beyond the IncisionBACKGROUND : Although primary therapy in...
Colorectal Cancer GuidelinesThe American Society of Colon and Rectal...
Familial Investigations of Childhood Cancer PredispositionWhile it is well recognized that heredit...
Bioabsorbable Staple Line Reinforcement in Colorectal,Coloanal and Ileoanal AnastomosesThe primary purpose of this prospective,...